Skip to main content
Clinical Trials/EUCTR2013-003352-20-DE
EUCTR2013-003352-20-DE
Active, not recruiting
Phase 1

Correlation of functional and structural outcomes with serum antibody profiles in patients with neovascular age-related macular degeneration treated with ranibizumab and healthy subjects: a prospective, controlled monocenter trial - CAPTAI

niversity Medical Center of Johannes -Gutenberg University Mainz0 sites70 target enrollmentMay 3, 2016

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
eovascular age-related macular degeneration (AMD)
Sponsor
niversity Medical Center of Johannes -Gutenberg University Mainz
Enrollment
70
Status
Active, not recruiting
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
May 3, 2016
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
niversity Medical Center of Johannes -Gutenberg University Mainz

Eligibility Criteria

Inclusion Criteria

  • Main inclusion criteria (patients):
  • Subjects meeting all of the following criteria will be considered for enrolment to the trial:
  • \-Male or female
  • \-Age \= 50 years
  • \-Subfoveal, juxtafoveal and/or extrafoveal choroidal neovascularisation due to neovascular age\-related macular degeneration
  • \-Visual acuity of 20/400 or better in the study eye
  • Main inclusion criteria (healthy volunteers):
  • \-Male or female
  • \-Age \= 50 years
  • Are the trial subjects under 18? no

Exclusion Criteria

  • Main exclusion criteria (patients):
  • Subjects presenting 1 of the following criteria will not be enrolled in the trial:
  • \-Inability to obtain fluorescein angiography
  • \-Ophthalmic surgery or laser \<3 months before enrolment in one or both eyes
  • \-Any history of intravitreal steroids
  • \-Systemic and/or intravitreal anti\-VEGF\-treatment or ocular laser \< 3 months before enrolment in one or both eyes
  • \-Patients with hypersensitivity against ranibizumab
  • \-Inability to give informed consent to participate in the study (legal representative is accepted)
  • \-Pregnancy, lactation or women who are of childbearing age and not using medically
  • acceptable effective contraception.

Outcomes

Primary Outcomes

Not specified

Similar Trials